Global Ticagrelor Market Report 2026: Outlook on Opportunities & Challenges

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Forecasted Market Size of the Ticagrelor Market by 2030?
The ticagrelor market size has grown strongly in recent years. It will grow from $1.93 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of antiplatelet therapies, growing cardiovascular disease prevalence, expansion of hospital pharmacy networks, increasing clinical trials for cardiovascular drugs, rising awareness of heart attack and stroke risks.

The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to launch of extended-release ticagrelor tablets, expansion of retail and online pharmacy distribution, rising adoption of personalized cardiovascular treatment, increasing government initiatives for cardiovascular disease prevention, integration with digital health monitoring systems. Major trends in the forecast period include rising use of ticagrelor in acute coronary syndrome management, growing preference for oral antiplatelet therapy over injectable options, expansion of hospital and ambulatory cardiology services, increasing awareness of stroke and myocardial infarction prevention, development of extended-release ticagrelor formulations.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report

Which Drivers Are Positively Impacting the Ticagrelor Market?
The increasing prevalence of cardiovascular diseases is expected to propel the growth of the ticagrelor market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. The increasing prevalence of cardiovascular diseases is primarily attributed to poor diet, as the excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels, all of which are major risk factors for heart-related conditions. Ticagrelor helps in treating cardiovascular diseases by preventing platelet aggregation, reducing the risk of blood clots. It improves patient outcomes by lowering the chances of heart attacks and strokes, especially in high-risk individuals. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ticagrelor market.

Which Are the Leading Segments in the Ticagrelor Market?
The ticagrelor market covered in this report is segmented –

1) By Type: 90 mg Tablet, 60 mg Tablet
2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications
5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users

What Are the Significant Trends in the Ticagrelor Market Across Regions?
Major companies operating in the ticagrelor market are focusing on obtaining regulatory approvals to expand product indications, increase market access, and strengthen their competitive positioning. Regulatory approvals refer to the official permission granted by government authorities to market and sell a product, ensuring it meets safety, efficacy, and quality standards. For instance, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg and tentative approval for the 60 mg strength. These tablets are used to reduce the risk of cardiovascular events and work by inhibiting platelet aggregation, thereby preventing the formation of blood clots.

What Are the Top Companies to Watch in the Ticagrelor Market?
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.

Get the full ticagrelor market report here:
https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report

Which Regions Are Driving the Most Demand in the Ticagrelor Market?
North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn

 

Comments

Post a Comment

Popular posts from this blog

Thrombosis And Hemostasis Biomarkers Industry Projected to Experience Accelerated Growth by 2030

Image
 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided. What Is the Projected Growth Rate of the Thrombosis And Hemostasis Biomarkers Market Through 2030? The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $5.17 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of coagulation biomarkers, reliance on manual and semi-automated analyzers, increasing prevalence of cardiovascular disorders, growing diagnostic laboratory infrastructure, rising awareness of thrombosis and he...
Read more

Viral Vector Production (Research-Use) Industry Forecasted for Rapid Expansion, Reaching $3.56 Billion by 2030

Image
The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided. What Is the Current Market Size and Growth Rate of the Viral Vectors And Plasmid DNA Market? The viral vector production (research-use) market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing investment in gene therapy research, expansion of academic and translational research programs, availability of advanced cell culture technologies, rising use of viral vectors in oncology studies, growth of contract research acti...
Read more

Trastuzumab Biosimilars Industry Revenue to Reach $24.48 Billion by 2030 with CAGR of 28.9% (2026-2030)

Image
 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided. What Is the Growth Potential of the Traumatic Brain Injury Biomarkers Market in the Next Decade? The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2025 to $8.86 billion in 2026 at a compound annual growth rate (CAGR) of 28.5%. The growth in the historic period can be attributed to high incidence of HER2 positive breast cancer, loss of trastuzumab patent exclusivity, rising oncology drug costs, regulatory biosimilar pathways, hospital oncology adoption. The trastuzumab biosimilars market size is expected to see exponen...
Read more